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As a new strain of virus emerged in 2013, avian influenza A (H7N9) virus is a threat to the public health, due to its high lethality
and pathogenicity. Furthermore, H7N9 has already generated various mutations such as neuraminidase R294K mutation which
could make the anti-influenza oseltamivir less effective or ineffective. In this regard, it is urgent to develop new effective anti-
H7N9 drug. In this study, we used the general H7N9 neuraminidase and oseltamivir-resistant influenza virus neuraminidase as the
acceptors and employed the small molecules including quercetin, chlorogenic acid, baicalein, and oleanolic acid as the donors to
perform the molecular docking for exploring the binding abilities between these small molecules and neuraminidase. The results
showed that quercetin, chlorogenic acid, oleanolic acid, and baicalein present oseltamivir-comparable high binding potentials with
neuraminidase. Further analyses showed that R294K mutation in neuraminidase could remarkably decrease the binding energies
for oseltamivir, while other small molecules showed stable binding abilities with mutated neuraminidase. Taken together, the
molecular docking studies identified four potential inhibitors for neuraminidase of H7N9, which might be effective for the drug-
resistant mutants.
1. Introduction
As the WHO reported on June 27, 2014, there were 450
laboratory-confirmed cases of avian influenza A (H7N9)
virus human infection including 165 deaths (http://www.who
.int). Most patients presented with severe pneumonia, acute
respiratory distress syndrome (ARDS), and multiple organ
failure [1, 2]. Sequence analysis indicated that H7N9 gene
descended from avian species, and what is more, the other
six genes originated from H9N2 [1–3]. Since the H7N9
virus could bind to both the avian and human receptors,
the potential risk of spreading between avian species and
human was highly increased [2]. Previously, it was observed
that the Asp701Asn mutation in PB2 and the Ser31Asn
mutation in hemagglutinin increased the adaptability to
mammals, and the Ser31Asn mutation of M2 contributed
at least partly to the resistance of antivirus drugs including
amantadine and rimantadine [3, 4]. These mutations made
the treatment of H7N9 virus infected patients more difficult
and increased the threats to public health.The neuraminidase
inhibitor oseltamivir was reported to be effective and safe
for therapy of influenza A [5] and employed in a number
of H7N9 cases. Although a number of cases were cured
[6, 7], oseltamivir was still invalid for a part of cases and the
efficiency is still debatable [8, 9]. Recently, Wu et al. solved
the structures for neuraminidases of A/Anhui/1/2013 (N9,
R294) andA/Shanghai/1/2013 (N9, K294), which showed that
the mutation of R294K could induce conformation changes
and generate oseltamivir resistance through interfering with
the binding of oseltamivir carboxylate [10]. Furthermore, the
authors proposed that the drug resistance caused bymutation
of R294K in H7N9 was more serious than that caused
by mutation of H274Y in H7N1 [10]. Taken together, the
development of new inhibitors for mutated neuraminidase is
urgently needed.
Recently, molecular modeling and computational chem-
istry based computer-aided drug design provided great
help for modern drug development [11]. Software programs
such as AutoDock were widely used to search potential
inhibitor for protein targets [12]. Previously, traditional
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Chinese medicine has been demonstrated to have antivirus
ability according to the clinical data, and a number of small
molecules such as quercetin, chlorogenic acid, oleanolic acid,
and baicalein were regarded as active molecules [13]. For
example, quercetin could serve as the inhibitor of Bcl-2
and Bcl-xL through binding with the BH3 domain, which
promoted cancer cell apoptosis [14, 15]. Chlorogenic acid
could protect theApoEknockoutmice against atherosclerosis
through accelerating the cholesterol efflux frommacrophages
[16, 17]. Baicalein was identified as the inhibitor of neu-
raminidase for pandemic 2009 H1N1 and also inhibited
interleukin-1 beta and TNF-alpha mediated inflammation
[18, 19]. Through inducing autophagy, oleanolic acid could
inhibit the proliferation and invasiveness in K-ras trans-
formed cells and induce Nrf-2 related antioxidant to reduce
ethanol-induced liver injury [20, 21]. However, whether these
small molecules could inhibit the neuraminidase of H7N9 is
still unclear.
In this study, we employed the strategy of molecule
docking to explore potential H7N9 neuraminidase inhibitors
from small molecules including quercetin, chlorogenic acid,
oleanolic acid, and baicalein, which were bioactive compo-
nents in traditional Chinese medicine. It was observed that
these small molecules showed high binding energies with
neuraminidases from A/Anhui/1/2013. The binding energies
for these small molecules were comparable with oseltamivir,
which indicated that the molecules were potential inhibitors
for neuraminidase. Furthermore, the results showed a weak
binding energy between oseltamivir and neuraminidase
from A/Shanghai/1/2013, which was consistent with the
oseltamivir resistance of H7N9 A/Shanghai/1/2013. However,
the four molecules quercetin, chlorogenic acid, oleanolic
acid, and baicalein showed robust binding energies with neu-
raminidase from A/Shanghai/1/2013. Taken together, these
molecules were potential neuraminidase inhibitors which
might be helpful for anti-influenza drug development.
2. Materials and Methods
2.1. Molecular Structure Preparing. To perform themolecular
docking between neuraminidase and potential inhibitors,
we employed the H7N9 neuraminidase structures of
A/Anhui/1/2013 (PDB code: 4MWQ) and A/Shanghai/1/2013
(PDB code: 4MWW), which were solved by Wu et al. at the
resolutions of 2.00 Å and 1.90 Å, respectively [10]. The PDB
files for these proteins were downloaded from the RCSB
Protein Data Bank (available at http://www.rcsb.org) [22].
The water and nonprotein molecules in the PDB files were
removed, while only neuraminidase monomer structures
were reserved. All the visualizations of molecular structures
were performed with PyMOL, which is state-of-the-art
software, to present the supercomplexes of proteins and
small molecules (Version 1.7.2, available at http://pymol.org)
[23]. Four small molecules including quercetin, chlorogenic
acid, oleanolic acid, and baicalein from traditional Chinese
medicine were selected for molecular docking based on
the following principles: (1) the molecules should be
identified from traditional Chinese medicine; (2) the
molecules should have been studied previously and be
commercially available. The structures in mol2 file format of
the five small molecules, including oseltamivir carboxylate
(ZINC03929509), quercetin (ZINC03869685), chlorogenic
acid (ZINC02138728), oleanolic acid (ZINC03785416), and
baicalein (ZINC03943903), were retrieved from the ZINC
database, which is a free public resource for ligand molecules
(available at http://zinc.docking.org) [24, 25].
2.2. Molecular Docking. In this study, we employed Auto-
Dock software (Version 4.2, available at http://autodock
.scripps.edu) to perform molecular docking. The AutoDock
is an automated docking program designed for prediction
of the binding among small molecules such as substrates or
drug candidates and the receptor with known 3D structure
[12]. AutoDockTools software (Version 1.5.6, also available
at http://autodock.scripps.edu), the graphical user interface
(GUI) program for setting up AutoDock software, was used
to prepare the procedures of docking [12]. The volume of the
grid box was set as 60 × 50 × 60 with the default 0.375 Å
spacing, and the number of docking runs was set as 100.
The neuraminidase structures were used as the receptor for
docking with the small molecules. Since the active sites of
neuraminidase in influenza A were highly conserved, the
docking pocket was set as the eight key residues including
Arg-118, Asp-151, Arg-152, Arg-224, Glu-276, Arg-292, Arg-
371, and Tyr-406 [26–28]. The chemoinformatic analyses
of potential toxicities and promiscuities for the five small
molecules were performed with FAF-Drugs3 software (avail-
able at http://fafdrugs3.mti.univ-paris-diderot.fr) [29].
3. Result and Discussion
3.1. Characterizing the Structures of the Small Molecules
for Molecular Docking. In this study, five small molecules
including oseltamivir carboxylate (Figure 1(a)), quercetin
(Figure 1(b)), baicalein (Figure 1(c)), chlorogenic acid
(Figure 1(d)), and oleanolic acid (Figure 1(e)) were employed
for docking with neuraminidase to explore the potential
inhibitor. Previously, it was observed that the oseltamivir
phosphate is the prodrug without antivirus activity while
its product of metabolism oseltamivir carboxylate is active
[30]. Thus, in this study, the oseltamivir carboxylate was
employed for molecular docking. The chemoinformatic
analyses were performed with the FAF-Drugs3 software [29]
to further understand the properties of the small molecules.
Since the hydrogen bonds (H-bonds) were critical for the
interactions and binding affinity between the protein and
small molecules, we analyzed the H-bond donors and
acceptors of these small molecules. It was observed that
oseltamivir carboxylate and quercetin, chlorogenic acid and
baicalein have five and six H-bond donors, respectively, while
oleanolic acid has two (Table 1). Baicalein has 11 H-bond
acceptors, while chlorogenic acid, quercetin, oseltamivir
carboxylate, and oleanolic acid have 9, 7, 6, and 3 H-bond
acceptors, respectively (Table 1). These results showed that
quercetin, chlorogenic acid, oleanolic acid, and baicalein had
the potential to form H-bonds with proteins. Furthermore,
the potential toxicities and promiscuities were analyzed by
the FAF-Drugs3 software [29]. It was observed that baicalein,
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Figure 1:The molecular structures for the five small molecules: (a) oseltamivir carboxylate; (b) quercetin; (c) baicalein; (d) chlorogenic acid;
(e) oleanolic acid.
chlorogenic acid, quercetin, and oseltamivir carboxylate have
low toxicities and promiscuities according to the threshold
of log𝑃 < 3 and tPSA > 75 (Table 1). Furthermore, oleanolic
acid has the log𝑃 of 7.49 and tPSA of 60.36 (Table 1).
However, oleanolic acid was proved as a drug for human
liver disorders treatment [31]. Thus, it seemed that four small
molecules had limited toxicities and promiscuities and were
proper for further drug development.
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Table 1: The chemoinformatic analyses of the small molecules with FAF-Drugs3 software.
MW log𝑃 tPSA Rotatable bonds HB donors HB acceptors Oral bioavailability
(VEBER)
Oral bioavailability
(EGAN)
Oseltamivir carboxylate 285.36 −1.87 106.1 6 5 6 Good Good
Quercetin 302.24 2.17 134.2 1 5 7 Good Good
Chlorogenic acid 354.31 −0.42 167.6 5 6 9 Good Good
Oleanolic acid 456.7 7.49 60.36 1 2 3 Good Good
Baicalein 446.36 1.11 190 4 6 11 Good Good
Table 2: The energies for the binding between the small molecules and A/Anhui/1/2013 neuraminidase.
Molecules RMSD ( ́Å) (vdW +Hbond + desolv)
energy (kcal/mol)
Electrostatic
energy (kcal/mol)
Total internal
energy (kcal/mol)
The best docking
energy (kcal/mol)
Inhibition
constant (nM)
Oseltamivir carboxylate — −7.24 −3.46 −11.47 −9.38 132.26
Quercetin 0.38 −6.69 −1.27 −11.2 −9.41 126.87
Chlorogenic acid 0.33 −10.24 −3.11 −15.21 −12.23 1.09
Oleanolic acid 0.81 −6.18 −2.2 −11.79 −11.2 6.19
Baicalein 0.38 −8.69 −3.3 −18.95 −11.45 4.02
Table 3: The energies for the binding between the small molecules and A/Shanghai/1/2013 neuraminidase.
Molecules RMSD ( ́Å) (vdW +Hbond + desolv)
energy (kcal/mol)
Electrostatic
energy (kcal/mol)
Total internal
energy (kcal/mol)
The best docking
energy (kcal/mol)
Inhibition
constant (nM)
Oseltamivir carboxylate — −4.22 −3.94 −9 −6.91 8.59𝐸 + 03
Quercetin 1.09 −6.17 −1.34 −11.03 −9.24 168.62
Chlorogenic acid 0.83 −6.98 −2.42 −12.8 −9.82 63.6
Oleanolic acid 0.42 −4.36 −4 −10.11 −9.51 106.11
Baicalein 0.73 −6.57 −3.28 −16.23 −10.23 27.11
3.2. Molecular Docking between NA and Small Molecules. The
molecular docking was performed among the neuramini-
dases from H7N9 A/Anhui/1/2013 and A/Shanghai/1/2013.
Oseltamivir carboxylate could serve as a control to evaluate
the neuraminidase binding ability of other molecules. The
conformation variations, binding energies, and inhibition
constants for the molecular docking among neuraminidase
and small molecules were presented in Figure 2 and Tables 2
and 3. The calculated root mean square deviations (RMSDs)
indicated that the conformation variations among neuramin-
idases binding with different small molecules were limited,
while A/Shanghai/1/2013 neuraminidase had moderate large
variations (Tables 2-3). It was observed that the A/Anhui/1/
2013 neuraminidase binding energies for oseltamivir carbox-
ylate and quercetin were almost the same, which were
−9.38 kcal/mol and−9.41 kcal/mol, respectively, while chloro-
genic acid, oleanolic acid, and baicalein have higher binding
energies as −12.23 kcal/mol, −11.20 kcal/mol, and −11.45 kcal/
mol, separately. The inhibition constants calculated for osel-
tamivir carboxylate, quercetin, chlorogenic acid, oleanolic
acid, and baicalein were 132.26, 126.87, 1.09, 6.19, and
4.02 nM, respectively (Table 2). For the A/Shanghai/1/2013
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Figure 2: The binding free energies for small molecules and neu-
raminidase from H7N9 A/Anhui/1/2013 and A/Shanghai/1/2013.
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Figure 3:The local structure of the docking complexes for small molecules and neuraminidase: (a) oseltamivir carboxylate and (b) quercetin.
neuraminidase, the binding energies for oseltamivir carbox-
ylate, quercetin, chlorogenic acid, oleanolic acid, and bai-
calein were −6.91 kcal/mol, −9.24 kcal/mol, −9.82 kcal/mol,
−9.51 kcal/mol, and −10.32 kcal/mol. It was obvious that osel-
tamivir carboxylate showed weaker binding ability for
A/Shanghai/1/2013 neuraminidase than A/Anhui/1/2013,
which was consistent with the observation that A/Shang-
hai/1/2013 has resistance for oseltamivir [10]. Other molecu-
les including chlorogenic acid, oleanolic acid, and baicalein
also presented the decrease of binding energies; quercetin
showed robust binding abilities for neuraminidases from
H7N9 A/Anhui/1/2013 and A/Shanghai/1/2013. The inhibi-
tion constants calculated for oseltamivir carboxylate, quer-
cetin, chlorogenic acid, oleanolic acid, and baicalein were
8.59𝐸 + 03, 168.62, 63.6, 106.11, and 27.11 nM, respectively
(Table 2), which also indicated that H7N9 neuraminidase
had significant oseltamivir resistance. Furthermore, the
detailed results for the top 3 scored poses for each small
molecule were presented in Supplementary Table S1 (see
Supplementary Table S1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/480764).
3.3. Structural Insights of the Docking Complex. To further
dissect the interaction between neuraminidase and the small
molecules, the structures in complex derived from the best
dock results with neuraminidase for oseltamivir carboxylate
(Figure 3(a)), quercetin (Figure 3(b)), chlorogenic acid
(Figure 4(a)), oleanolic acid (Figure 4(b)), and baicalein
(Figure 5) derived from molecular docking were shown.
From the molecule docking among A/Anhui/1/2013
neuraminidase and small molecules, it was observed that
there were 18 H-bonds in the neuraminidase-chlorogenic
acid complex (Figure 4(a)), while quercetin (Figure 3(b)) has
14 H-bonds with neuraminidase. Oseltamivir carboxylate
(Figure 3(a)) and baicalein (Figure 5) both have 12 H-bonds
with neuraminidase, while oleanolic acid (Figure 4(b))
has 5. The H-bond residues for neuraminidase from
A/Anhui/1/2013 and A/Shanghai/1/2013 were provided in
Tables 4 and 5, respectively. These results indicated that
chlorogenic acid, quercetin, and baicalein could intensively
bind neuraminidase through H-bonds. For A/Shang-
hai/1/2013 neuraminidase, chlorogenic acid could form 17
H-bonds (Figure 4(a)), which indicated that chlorogenic
acid has high potential of neuraminidase inhibition. It was
interesting that the H-bonds for baicalein (Figure 5) and
oleanolic acid (Figure 4(b)) were increased to 15 and 8
for A/Shanghai/1/2013 neuraminidase compared to those
from A/Anhui/1/2013, while there were 9 and 11 H-bonds
for oseltamivir carboxylate (Figure 3(a)) and quercetin
(Figure 3(b)), respectively. These results indicated that
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Table 4: The residues for the H-bonds between the small molecules and A/Anhui/1/2013 neuraminidase.
Molecules H-bond residues
Oseltamivir carboxylate ARG-292, ASP-151, GLU-277, ARG-118, ARG-371, and TYR-406
Quercetin ARG-118, GLU-119, GLU-277, ARG-292, GLU-276, ARG-156, TRP-178, and ARG-224
Chlorogenic acid ASP-151, ARG-152, ARG-224, ARG-292, ASN-294, ASN-346, ARG-371, and TYR-406
Oleanolic acid ARG-118, GLU-276, and ARG-371
Baicalein ARG-292, GLU-277, ARG-152, ASP-151, ARG-118, ARG-371, and TYR-406
Chlorogenic acid
A/Anhui/1/2013 A/Shanghai/1/2013
(a)
Oleanolic acid
A/Anhui/1/2013 A/Shanghai/1/2013
(b)
Figure 4: The local structure of the docking complexes for small molecules and neuraminidase: (a) chlorogenic acid and (b) oleanolic acid.
Baicalein
A/Anhui/1/2013 A/Shanghai/1/2013
Figure 5: The local structure of the docking complexes for baicalein and neuraminidase.
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Table 5: The residues for the H-bonds between the small molecules and A/Shanghai/1/2013 neuraminidase.
Molecules H-bond residues
Oseltamivir carboxylate ARG-118, ASP-151, ARG-152, and ARG-371
Quercetin ARG-224, GLU-277, LYS-292, LYS-350, ASN-325, ARG-371, LYS-432, and TYR-406
Chlorogenic acid ASN-346, ASN-294, LYS-292, GLU-276, ARG-224, GLU-277, ARG-152, ASP-151, TYR-406, and ARG-371
Oleanolic acid ARG-118, ARG-152, ARG-371, and TYR-406
Baicalein ARG-151, ARG-118, ARG-152, ARG-224, GLU-276, LYS-292, ASN-294, and GLY-348
the oseltamivir resistance caused by R294K mutation for
neuraminidase in A/Shanghai/1/2013 might be generated
from theH-bond loss, while othermoleculesmight overcome
the resistance. Furthermore, other known inhibitors of neu-
raminidase including zanamivir, peramivir, and laninamivir
had similar structures and presented similar inhibition
abilities for neuraminidase from A/Anhui/1/2013 [10].
However, they also showed significantly decreased inhibition
for A/Shanghai/1/2013 [10]. Since the small molecules
including quercetin, chlorogenic acid, oleanolic acid, and
baicalein had longer structures and there was considerable
room for improvements, we anticipated that they had great
potential to overcome the drug resistance of H7N9 mutant.
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